StockData
Corcept Therapeutics Inc logo

Corcept Therapeutics Inc (CORT) stock

CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30328% above fair value
$64.98−2.81 (-4.15%)

Close on Nov 19, 2026Market cap $7.02BP/E 154.7Yield –

Corcept Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Corcept Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $830.81M, up 16.0% year over year. For fiscal 2025 it was $761.41M, up 12.8% from the year before. Over ten years it grew 31.2% a year on average. The highest annual figure on record is $761.41M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$761.41M+12.8%
FY2024Dec 31, 2024$675.04M+39.9%
FY2023Dec 31, 2023$482.38M+20.0%
FY2022Dec 31, 2022$401.86M+9.8%
FY2021Dec 31, 2021$365.98M+3.4%
FY2020Dec 31, 2020$353.87M+15.5%
FY2019Dec 31, 2019$306.49M+22.0%
FY2018Dec 31, 2018$251.25M+57.8%
FY2017Dec 31, 2017$159.20M+95.8%
FY2016Dec 31, 2016$81.32M+61.7%
FY2015Dec 31, 2015$50.29M+89.4%
FY2014Dec 31, 2014$26.55M+156.4%
FY2013Dec 31, 2013$10.36M+213.2%
FY2012Dec 31, 2012$3.31M+11303.4%
FY2009Dec 31, 2009$29.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$256.15M+31.7%
Q1 FY2026Mar 31, 2026$164.90M+4.9%
Q4 FY2025Dec 31, 2025$202.13M+11.1%
Q3 FY2025Sep 30, 2025$207.64M+13.7%
Q2 FY2025Jun 30, 2025$194.43M+18.7%
Q1 FY2025Mar 31, 2025$157.21M+7.1%
Q4 FY2024Dec 31, 2024$181.89M+34.3%
Q3 FY2024Sep 30, 2024$182.55M+47.7%
Q2 FY2024Jun 30, 2024$163.80M+39.1%
Q1 FY2024Mar 31, 2024$146.81M+39.0%
Q4 FY2023Dec 31, 2023$135.41M+31.4%
Q3 FY2023Sep 30, 2023$123.60M+21.5%
Q2 FY2023Jun 30, 2023$117.72M+13.9%
Q1 FY2023Mar 31, 2023$105.65M+12.8%
Q4 FY2022Dec 31, 2022$103.06M+4.3%
Q3 FY2022Sep 30, 2022$101.73M+5.8%
Q2 FY2022Jun 30, 2022$103.39M+12.9%
Q1 FY2022Mar 31, 2022$93.69M+17.9%
Q4 FY2021Dec 31, 2021$98.82M+15.3%
Q3 FY2021Sep 30, 2021$96.13M+11.4%
Q2 FY2021Jun 30, 2021$91.59M+3.4%
Q1 FY2021Mar 31, 2021$79.44M-14.8%
Q4 FY2020Dec 31, 2020$85.74M-2.5%
Q3 FY2020Sep 30, 2020$86.33M+5.9%
Q2 FY2020Jun 30, 2020$88.57M+22.6%
Q1 FY2020Mar 31, 2020$93.25M+43.8%
Q4 FY2019Dec 31, 2019$87.90M+31.5%
Q3 FY2019Sep 30, 2019$81.51M+26.5%
Q2 FY2019Jun 30, 2019$72.26M+16.0%
Q1 FY2019Mar 31, 2019$64.83M+12.4%
Q4 FY2018Dec 31, 2018$66.83M+25.4%
Q3 FY2018Sep 30, 2018$64.45M+50.7%
Q2 FY2018Jun 30, 2018$62.31M+75.2%
Q1 FY2018Mar 31, 2018$57.66M+108.9%
Q4 FY2017Dec 31, 2017$53.28M+123.8%
Q3 FY2017Sep 30, 2017$42.76M+96.8%
Q2 FY2017Jun 30, 2017$35.56M–
Q1 FY2017Mar 31, 2017$27.60M–
Q4 FY2016Dec 31, 2016$23.81M–
Q3 FY2016Sep 30, 2016$21.73M–

More Corcept Therapeutics figures

See a number that looks wrong?